​

Molecular Partners (MOLN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MOLN Stock Forecast

Molecular Partners (MOLN) stock forecast, based on 2 Wall Street analysts, predicts a 12-month average price target of $29.00, with a high of $29.00 and a low of $29.00. This represents a 455.56% increase from the last price of $5.22.

- $6 $12 $18 $24 $30 High: $29 Avg: $29 Low: $29 Last Closed Price: $5.22

MOLN Stock Rating

Molecular Partners stock's rating consensus is Buy, based on 2 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (50.00%), 1 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 2 0 1 1 Strong Sell Sell Hold Buy Strong Buy

MOLN Forecast vs Benchmarks

TypeNameUpside
StockMolecular Partners455.56%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$5.22$5.22$5.22
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-21--3
Dec, 24-21--3
Nov, 24-22--4
Oct, 24-22--4
Sep, 24-12--3
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 27, 2022Leerink Partners$29.00$13.89108.78%455.56%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Apr 27, 2022SVB LeerinkOutperformOutperformhold
Apr 27, 2022Credit SuisseNeutraldowngrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.51$-2.06$3.63$-1.89-----
Avg Forecast$-1.48$-1.86$3.43$-1.93$-1.80$-2.03$-2.13$-2.82$-2.72
High Forecast$-1.54$-1.93$3.43$-2.30$-2.00$-2.46$-2.88$-2.82$-2.72
Low Forecast$-1.43$-1.79$3.43$-1.61$-1.61$-1.67$-1.37$-2.82$-2.72
Surprise %69.59%10.75%5.83%-2.07%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.34M$9.33M$189.56M$7.04M-----
Avg Forecast$28.36M$15.35M$180.08M$5.84M$4.60M$2.37M$15.04M$16.15M$28.89M
High Forecast$27.54M$14.90M$180.08M$5.44M$4.38M$2.37M$15.04M$16.15M$28.89M
Low Forecast$29.18M$15.79M$180.08M$6.24M$4.81M$2.37M$15.04M$16.15M$28.89M
Surprise %-67.05%-39.21%5.26%20.51%-----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-62.76M$-63.78M$117.85M$-61.98M-----
Avg Forecast$-48.61M$-61.06M$112.34M$-61.98M$-62.59M$-74.70M$-79.50M$-92.50M$-89.19M
High Forecast$-50.43M$-63.34M$112.34M$-75.23M$-65.40M$-80.48M$-94.38M$-92.50M$-89.19M
Low Forecast$-46.78M$-58.76M$112.34M$-52.89M$-52.87M$-54.61M$-45.01M$-92.50M$-89.19M
Surprise %29.11%4.46%4.91%------

MOLN Forecast FAQ

Is Molecular Partners stock a buy?

Molecular Partners stock has a consensus rating of Buy, based on 2 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Molecular Partners is a favorable investment for most analysts.

What is Molecular Partners's price target?

Molecular Partners's price target, set by 2 Wall Street analysts, averages $29 over the next 12 months. The price target range spans from $29 at the low end to $29 at the high end, suggesting a potential 455.56% change from the previous close price of $5.22.

How does Molecular Partners stock forecast compare to the average forecast of its sector, industry, and investment themes?

Molecular Partners stock forecast shows a 455.56% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Molecular Partners over the past three months?

  • January 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Molecular Partners’s EPS forecast?

Molecular Partners's average annual EPS forecast for its fiscal year ending in December is -1.8 for 2024, a -4.76% decrease from the reported $-1.89 in 2023. The prediction for 2025 is $-2.03, $-2.13 for 2026, $-2.82 for 2027, and $-2.72 for 2028.

What is Molecular Partners’s revenue forecast?

Molecular Partners's average annual revenue forecast for its fiscal year ending in December is $4.6M for 2024, a -34.64% decrease from the reported $7.04M in 2023. The forecast for 2025 is $2.37M, $15.04M for 2026, $16.15M for 2027, and $28.89M for 2028.

What is Molecular Partners’s net income forecast?

For its fiscal year ending in December, Molecular Partners's average annual net income forecast is $-62.591M for 2024, reflecting an 0.98% increase from the reported $-61.984M in 2023. The projection for 2025 is $-74.7M, $-79.5M for 2026, $-92.495M for 2027, and $-89.192M for 2028.